Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORB | Q92753 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27988288 | 0.80 | HTT (0.34) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL28810669 | 0.78 | KDM4E (0.42) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL27800255 | 0.76 | KDM4E (0.35) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL27926398 | 0.76 | FGFR1 (0.34) | — | |
| SCHEMBL29859977 | 0.73 | MAPT (0.39) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL27800257 | 0.72 | ALPL (0.33) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL27635797 | 0.71 | ALPL (0.62) | ALPL | |
| SCHEMBL27951101 | 0.71 | ALPL (0.48) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL27757070 | 0.70 | PLA2G10 (0.48) | RORBKDM4EMAPTHTTALPL | |
| SCHEMBL27800253 | 0.70 | CYP2D6 (0.36) | RORBMAPTALPLMETAP2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496901-B | The manufacture method of anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |